pH/redox sensitive nanoparticles with platinum(iv) prodrugs and doxorubicin enhance chemotherapy in ovarian cancer-Reference-Cited by-同舟云学术

pH/redox sensitive nanoparticles with platinum(iv) prodrugs and doxorubicin enhance chemotherapy in ovarian cancer

Published:2019 Issue:36 Volume:9 Page:20513-20517
ISSN:2046-2069
Container-title:RSC Advances
language:en
Short-container-title:RSC Adv.

Author:

Zhang Guyu¹²³⁴,Zhu Yimin⁵⁶⁷⁴,Wang Yushu⁸⁹¹⁰⁴,Wei Dengshuai¹¹¹²¹³¹⁴¹⁵,Wu Yixin¹⁶¹⁷¹⁸⁴,Zheng Liuchun¹¹¹²¹³¹⁴¹⁵^ORCID,Bai Huimin¹²³⁴,Xiao Haihua¹¹¹²¹³¹⁴¹⁵,Zhang Zhenyu¹²³⁴^ORCID

Affiliation:

1. Beijing Chaoyang Hospital Affiliated to Capital Medical University

2. Department of Gynaecological and Obstetric

3. Beijing 100000

4. P. R. China

5. Affiliated Guangdong Medical University

6. Department of Oncology

7. Zhanjiang 524000

8. Key Laboratory of Bio-based Material Science and Technology Ministry of Education

9. Northeast Forestry University

10. Harbin 150040

11. Beijing National Laboratory for Molecular Sciences

12. State Key Laboratory of Polymer Physics and Chemistry

13. Institute of Chemistry

14. Chinese Academy of Sciences

15. Beijing 100190

16. College of Life Science and Technology

17. Beijing University of Chemical Technology

18. Beijing 100029

Abstract

pH/redox sensitive, dual drug loaded nanoparticles were prepared from poly(ethylene glycol)-block-poly(l-lysine) (PEG-b-PLL) for improving cancer therapy.

Publisher

Royal Society of Chemistry (RSC)

Subject

General Chemical Engineering,General Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2019/RA/C9RA04034J

Reference24 articles.

1. Cancer statistics, 2019

2. A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis

3. Activity of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with cisplatin and doxorubicin in women with recurrent, platinum-resistant ovarian cancer: Preliminary clinical experience

4. Cisplatin versus Cisplatin plus Doxorubicin for Standard-Risk Hepatoblastoma

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Engineering Novel Amphiphilic Platinum(IV) Complexes to Co-Deliver Cisplatin and Doxorubicin;Molecules;2024-08-29

2. Targeting hypoxic and acidic tumor microenvironment by nanoparticles: A review;Journal of Drug Delivery Science and Technology;2024-06

3. Bacterial Flagellum–Drug Nanoconjugates for Carrier‐Free Immunochemotherapy;Small;2023-11-02

4. Magic shotgun over magic bullet for treatment of ovarian cancer via polymeric nanoparticles;Journal of Drug Delivery Science and Technology;2023-10

5. Biomedical Assessment of Silver Nanoparticles Derived from L-Aspartic Acid Against Breast Cancer Cell Lines and Bacteria Strains;BioNanoScience;2023-09-16